Pre-eclampsia (PE) is a pregnancy-specific disease that can progress to Eclampsia and result in seizure, coma and mortality mortality as well as neonatal death. PE is a major cause of prenatal and maternal death worldwide, yet to date there are no reliable diagnostics or biomarkers that can accurately predict the onset of PE. Miraculins, a company dedicated to the development and commercialization of diagnostic tests for diseases and conditions that are lacking highly sensitive and specific tests, is developing a PE diagnostic test. Under a patent issued in July called “Methods for Early Diagnosing of an Increased Risk of Preeclampsia,” Miraculins is investigating biomarkers that can predict the risk of PE based on the research of Dr.